measles, mumps, and rubella vaccine (MMR) Report issue

Vaccine Approved FDA
AACT PubChem

Active Ingredient History

NOW
  • Now
The MMR vaccine is a vaccine against measles, mumps, and rubella, abbreviated as MMR. The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least four weeks between the doses. After two doses, 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella. The vaccine is also recommended for those who do not have evidence of immunity, those with well-controlled HIV/AIDS, and within 72 hours of exposure to measles among those who are incompletely immunized. It is given by injection.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

attenuated measles mumps rubella | measles, mumps and rubella combined vaccine, live | measles, mumps and rubella vaccine | measles, mumps, and rubella vaccine | measles, mumps, and rubella virus vaccine live | measles, mumps, and rubella virus vaccine, live | measles virus enders edmonston strain (live, attenuated) / mumps virus jeryl lynn (level b) strain (live, attenuated) / rubella virus wistar ra 27/3 strain (live, attenuated) | mmr | mmrii | mmr ii | mmr-v | mmr vaxpro | mumps vaccine | trivivac vaccine | v419

Organizations (56)

Research & Development (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (53)

Approved Indications (1)


 

Virus Diseases

Experimental Indications - Clinical Trial Phases 1-4 (53)


 

Acute-Phase Reaction (Phase 2/Phase 3)

Arthritis, Juvenile (Phase 4)

Bacterial Infections (Phase 3)

Chickenpox (Phase 4)

Chikungunya Fever (Phase 2)

Communicable Diseases (Phase 2)

Condylomata Acuminata (Phase 3)

COVID-19 (Phase 4)

Dengue (Phase 3)

Diphtheria (Phase 3)

Diphtheria Toxoid (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Eczema (Phase 4)

Encephalitis, Japanese (Phase 3)

Esophageal and Gastric Varices (Phase 2)

Haemophilus influenzae (Phase 2)

Haemophilus influenzae type b (Phase 3)

Healthy Volunteers (Phase 3)

Hepatitis A (Phase 4)

Hepatitis B (Phase 2)

HIV (Phase 4)

HIV Infections (Phase 2)

Human papillomavirus 16 (Phase 4)

Hypersensitivity (Phase 4)

Immune System Diseases (Phase 4)

Infections (Phase 4)

Measles (Phase 4)

Measles-Mumps-Rubella Vaccine (Phase 4)

Meningitis (Phase 3)

Meningitis, Meningococcal (Phase 3)

Meningococcal Infections (Phase 3)

Mumps (Phase 4)

Mumps Vaccine (Phase 2)

Neisseria meningitidis (Phase 3)

Papillomavirus Infections (Phase 4)

Pertussis Vaccine (Phase 3)

Pneumococcal Infections (Phase 3)

Pneumococcal Vaccines (Phase 3)

Poliomyelitis (Phase 4)

Poliovirus Vaccines (Phase 2)

Psoriasis (Phase 1)

Respiratory Tract Infections (Phase 4)

Rotavirus (Phase 4)

Rubella (Phase 4)

Rubella Vaccine (Phase 2)

Severe Dengue (Phase 3)

Systemic Inflammatory Response Syndrome (Phase 3)

Tetanus (Phase 3)

Vaccines (Phase 4)

Virus Diseases (Phase 3)

Warts (Phase 4)

Whooping Cough (Phase 3)

Yellow Fever (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 95
  • # of Trial Organizations: 56

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue